The Bell Perspective

How the 'Dirty Soda' pioneer turned a founder's personal crisis into a powerful CSR model that drives growth, brand loyalty, and life-saving impact.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

With a new COO, a string of acquisitions, and Morgan Stanley's backing, Security 101 is executing a masterclass in scaling from a regional player to a national powerhouse.

Third Arc Bio's move to fund clinical development for a new cancer drug validates Adagene's SAFEbody platform, de-risking its finances and setting the stage.

Cincinnati's new Crown Network is moving from screens to streets, partnering with The Park to create an immersive Bengals game day hub. Is this the future?

The firm’s upcoming Town Hall reveals more than strong Q2 growth; it showcases a deliberate strategy to dominate the future of equitable, AI-assisted care.

Cure Alzheimer's Fund is recruiting top drug developers, including the mind behind Kisunla™, to steer its research—all while refusing industry money.

A new advisory firm in Dubai is more than a launch; it's a market signal. ZT Global's unique blend of U.S. operational muscle and GCC financial savvy is built to rewire cross-border investment.

Scotlynn's recent 'Best Company to Work For' award is no accident. It's a core part of a strategic playbook designed to fuel aggressive expansion.

TMCF's appointment of a renowned scholar isn't just a hire; it's a calculated move to rewire the ecosystem of Black innovation and economic power.

Assetara launches an AI-driven Web3 platform promising automated trading and gamified rewards. But behind the tech-savvy facade lie sky-high returns, an MLM structure, and pressing regulatory questions.

As TerrAscend executives head to a key investor conference, their pitch is about more than sales figures. It's a strategic play for institutional capital.

Record semiconductor equipment sales of $40.53B aren't just a market upswing; they signal a fundamental rewiring of the global tech supply chain by AI.

While most crypto projects sell a vision, Remittix is building a live financial ecosystem—and it's already processing millions before its token even lists.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

As enterprises race to deploy AI, one firm's near-perfect cybersecurity score reveals a new battleground: independently validated trust. What does it signal?

The beloved curl brand is expanding its territory with a new collection for all hair types. We analyze the strategy behind this ambitious, celebrity-backed move.

With its acquisition of TEAM Companies, DISA is betting on specialized tech to manage the risks of an expanding contractor workforce in high-stakes industries.

With top awards for work on Hangar One and the Harbor Bridge, BrandSafway shows how specialized access engineering is the unsung hero of modern construction.

Designed to rehabilitate impaired physicians, Physician Health Programs are now accused of being punitive traps, with claims of false diagnoses and profiteering.